Jeff Kindler, a lawyer tapped as a fresh face to lead drugmaker Pfizer out of its doldrums, is out, after just a little over four years as chairman and chief executive.

Kindler, 55, says he's retiring, after an exhausting run. Managing the world's largest drug company, as measured by sales, is nobody's idea of an easy job. And it's even tougher when you're playing beat the clock to find a replacement for Lipitor, the company's huge-selling cholesterol fighter that goes generic next year.

To read the full NPR story, click here.

Jeff Kindler, a lawyer tapped as a fresh face to lead drugmaker Pfizer out of its doldrums, is out, after just a little over four years as chairman and chief executive.

Kindler, 55, says he's retiring, after an exhausting run. Managing the world's largest drug company, as measured by sales, is nobody's idea of an easy job. And it's even tougher when you're playing beat the clock to find a replacement for Lipitor, the company's huge-selling cholesterol fighter that goes generic next year.

To read the full NPR story, click here.